SyntheMed REPEL-CV Receives Russian Approval

SyntheMed announced that its REPEL-CV barrier has received approval from the Ministry of Health of the Russian Federation for use in all patients who undergo open heart surgery.

Read more »

SyntheMed Receives Endorsement, New Patent

REPEL-CV, a bioresorbable anti-adhesion barrier developed by biomaterials company SyntheMed, has received an endorsement from Kids with Heart.

Read more »

SyntheMed Nominated for Frost & Sullivan Award

The Iselin, NJ-based company was recognized for its REPEL-CV Anti-Adhesion Barrier.

Read more »

SyntheMed’s REPEL-CV Approved by Australian Regulators

REPEL-CV, an anti-adhesion barrier developed by biomaterials company SyntheMed, has received approval by the Australian Therapeutic Goods Administration for use in open-heart surgery.

Read more »

State of the Art: Anti-Adhesion Barriers

Many patients are concerned about the external scars that form following surgical procedures, but a much greater risk can come from internal scarring. Adhesions are a type of post-surgical scar tissue that forms between two internal organs or surfaces that are normally separated.

Read more »